In vitro (induction of CXCR4-dependent cell death in leukemia and MM cell lines); in vivo (antitumor effect in leukemia, MM, NSCLC mouse xenograft models); clinical trials (NCT02826486, NCT01838395, and NCT02073019). This evidence concerns the gene CXCR4 and Miyoshi myopathy.